Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Safety and Immunogenicity of GARDASIL in Healthy Females 9–26 Years in Sub-Saharan Africa
2017-000110-35Phase 3
- Sponsor
- Merck & Co.
- Start
- Jan 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of qHPV vaccine in human papillomavirus infection, Cervical Cancer (CC) and anogenital warts, sponsored by Merck & Co. Primary endpoint: Primary Immunogenicity Endpoint (Phase A).
02
Drugs
qHPV vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)anogenital warts
Beyond the preview
Go deeper on 2017-000110-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000110-35.